Clinical Oncology NewsRituximab Maintenance for Elderly With Mantle Cell LymphomaClinical Oncology NewsA one–two punch against mantle cell lymphoma (MCL) in older patients has demonstrated the potential to improve an otherwise dismal prognosis. Resea…
Gilead Sciences Management Discusses Q3 2012 Results – Earnings Call …Seeking AlphaA third study evaluating 1101 with ofatumumab and CLL and two Phase III studies evaluating 1101 in combination with rituximab and with rituximab and bendamustine and i…
Watchful waiting still viable option for follicular lymphomaHealioThe aim was to identify parameters for initiating treatment in the rituximab (Rituxan, Genentech/Idec Pharmaceuticals) era and to determine how parameters for a watchful waiting strategy…
FDA seeks more data from Teva on Treanda cancer drugGlobesThe US Food and Drug Administration (FDA) is asking more data from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) about its first line treatment for non-Hodgkin lymphoma, Treanda, …
22.10.2012 – Warum Frauen besser auf die Therapie ansprechenDKG KrebsgesellschaftNoch besser sind ihre Überlebenschancen offenbar jedoch, wenn sie mit Rituximab behandelt werden. In der aktuellen Studie hatten Patienten mit zuvor unbehandeltem folliku…
Tadias MagazineBattling Cancer in Ethiopia: Interview with Cancer Survivor Tsige Birru-BentiTadias MagazineIn January 2010, I was diagnosed with Lymphoma B-Cell grade 2 cancer. Being in London, where facilities are in place my treatment was on the fast…
Beacon NewsFlashes – October 22, 2012The MDS BeaconPhase 2 Study To Investigate Treatment For Skin Thickening Due To Chronic Graft-Versus-Host Disease – A Phase 2 study comparing Rituxan (rituximab) and Gleevec (imatinib) for the treatment of skin …
Alemán revela fármaco de años 60 que mejora la vida en pacientes con linfomaABC.esEl científico ha resumido que el trabajo que él ha coordinado ha servido para comprobar que la bendamustina duplicó la supervivencia libre de enfermedad cuando se a…
Pharmacyclics Triggers Another Significant Milestone PaymentThe FINANCIALThe FINANCIAL — Pharmacyclics announced that the international, randomized Phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with r…
San Francisco ChronicleRoche cancer drugs and currency drive sales growthPharma TimesThe firm's top-selling drug was MabThera/Rituxan (rituximab), approved for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthr…